On June 4, 2026, the Supreme Court unanimously reversed the Federal Circuit in Hikma v. Amarin, holding that Amarin failed to plausibly allege that Hikma induced infringement of its patents covering icosapent ethyl under 35 U.S.C. ┬º 271(b). The decision marks a significant recalibration of the pleading standard applicable to induced-infringement claims premised on so-called “skinny labels,” and it materially strengthens the position of generic manufacturers who carve out patented indications under the Hatch-Waxman framework.
Writing for a unanimous Court, Justice Jackson clarified that a plaintiff asserting induced infringement must plausibly allege that the accused infringer engaged in active encouragement of infringing uses. Allegations that physicians could read a generic label as instructions to administer the drug for a patented indication, without more, do not satisfy the plausibility requirement. The Court emphasized that induced infringement is a specific-intent tort, and pleadings must reflect that demanding mental-state element rather than rely on inferences drawn from label content that has been deliberately narrowed to avoid the patented use.
The practical effect is a higher pleading threshold for branded drug makers seeking to keep skinny-label generics out of the market. To survive a motion to dismiss, complaints will need to identify concrete facts suggesting that the generic manufacturer actively promoted, marketed, or otherwise encouraged the patented indication, such as targeted communications to prescribers, sales-force activity directed at the carved-out use, or promotional materials that go beyond the four corners of the approved label. Conclusory references to label-reading inferences are unlikely to suffice.
For generic manufacturers, the ruling provides meaningful reassurance that good-faith use of the skinny-label pathway will not, standing alone, expose them to protracted infringement litigation. For branded patent holders, the decision counsels a more deliberate pre-suit investigation and a sharper evidentiary record focused on conduct evidencing intent. Companies on both sides of the Hatch-Waxman landscape should review their labeling, marketing, and litigation strategies in light of the Court’s clarified framework.
This alert is provided for general informational purposes only and does not constitute legal advice. Clients facing specific issues involving induced infringement, skinny labels, or Hatch-Waxman litigation should seek tailored counsel.